BioNexus Gene Lab Corp.
BGLC
$5.38
-$0.04-0.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -409.49% | -500.48% | -212.90% | 48.44% | 176.78% |
| Total Depreciation and Amortization | 32.38% | 35.14% | 44.78% | 67.58% | 28.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.14% | 111.48% | 82.08% | -110.32% | -413.49% |
| Change in Net Operating Assets | 65.58% | -8,069.23% | 3,437.10% | -100.66% | -1,313.01% |
| Cash from Operations | -9.76% | -2,115.32% | 91.08% | -62.29% | -2,724.79% |
| Capital Expenditure | -1,094.44% | 58.45% | -344.44% | -48.66% | 87.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -110.91% | -125.78% | 134.98% | 107.10% | 476.11% |
| Cash from Investing | -145.02% | -521.62% | 134.67% | 49.24% | 2,141.94% |
| Total Debt Issued | -- | -- | -110.61% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -72.44% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 2.94% | 7.69% | -- |
| Cash from Financing | -100.57% | -103.35% | -72.43% | -103.47% | 7,408.33% |
| Foreign Exchange rate Adjustments | 601.63% | 159.53% | -971.49% | 669.76% | 76.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.89% | -909.49% | 109.91% | -129.10% | -122.14% |